ERIS

Eris Lifesciences Share Price

₹1,380.30 -13.8 (-0.99%)

21 Dec, 2024 18:21

SIP TrendupStart SIP in ERIS

Start SIP

Performance

  • Low
  • ₹1,365
  • High
  • ₹1,407
  • 52 Week Low
  • ₹809
  • 52 Week High
  • ₹1,594
  • Open Price₹1,394
  • Previous Close₹1,394
  • Volume169,927

Investment Returns

  • Over 1 Month + 0.87%
  • Over 3 Month + 1%
  • Over 6 Month + 33.78%
  • Over 1 Year + 57.77%
SIP Lightning

Smart Investing Starts Here Start SIP with Eris Lifesciences for Steady Growth!

Invest Now

Eris Lifesciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 53.9
  • PEG Ratio
  • -5.6
  • Market Cap Cr
  • 18,790
  • P/B Ratio
  • 7.3
  • Average True Range
  • 52.18
  • EPS
  • 25.6
  • Dividend Yield
  • 0
  • MACD Signal
  • 23.04
  • RSI
  • 42.17
  • MFI
  • 64.97

Eris Lifesciences Financials

Eris Lifesciences Technicals

EMA & SMA

Current Price
₹1,380.30
-13.8 (-0.99%)
pointer
  • stock-down_img
  • Bullish Moving Average 5
  • stock-up_img
  • Bearish Moving Average 11
  • 20 Day
  • ₹1,428.20
  • 50 Day
  • ₹1,391.75
  • 100 Day
  • ₹1,318.54
  • 200 Day
  • ₹1,192.74

Resistance and Support

1383.93 Pivot Speed
  • R3 1,444.37
  • R2 1,425.43
  • R1 1,402.87
  • S1 1,361.37
  • S2 1,342.43
  • S3 1,319.87

What's your outlook on Eris Lifesciences?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Eris Lifesciences Ltd. is a leading Indian pharmaceutical company specializing in chronic and sub-chronic therapies. With 70% in-house manufacturing and a pan-India distribution network, Eris generates 86% of its revenue from chronic care, serving over 500,000 chemists nationwide.

Eris Lifesciences has an operating revenue of Rs. 2,495.89 Cr. on a trailing 12-month basis. An annual revenue growth of 20% is outstanding, Pre-tax margin of 21% is great, ROE of 15% is good. The company has a reasonable debt to equity of 25%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 23% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It has recently broken out of a base in its weekly chart and is trading around -3% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 40 which is a POOR score indicating inconsistency in earnings, a RS Rating of 70 which is FAIR indicating the recent price performance, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 67 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Eris Lifesciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-25 Quarterly Results
2024-08-02 Quarterly Results
2024-05-21 Audited Results & Fund Raising
2024-02-13 Quarterly Results
2023-11-08 Quarterly Results
Date Purpose Remarks
2022-08-16 INTERIM Rs.7.35 per share(735%)Interim Dividend
2021-08-06 INTERIM Rs.6.01 per share(601%)Interim Dividend

Eris Lifesciences F&O

Eris Lifesciences Shareholding Pattern

54.87%
17.03%
0.92%
8.01%
0%
10.52%
8.65%

About Eris Lifesciences

  • NSE Symbol
  • ERIS
  • BSE Symbol
  • 540596
  • Chairperson & Managing Director
  • Mr. Amit Bakshi
  • ISIN
  • INE406M01024

Similar Stocks to Eris Lifesciences

Eris Lifesciences FAQs

Eris Lifesciences share price is ₹1,380 As on 21 December, 2024 | 18:07

The Market Cap of Eris Lifesciences is ₹18789.9 Cr As on 21 December, 2024 | 18:07

The P/E ratio of Eris Lifesciences is 53.9 As on 21 December, 2024 | 18:07

The PB ratio of Eris Lifesciences is 7.3 As on 21 December, 2024 | 18:07

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23